Physician profile

Abhishek Bhardwaj

Internal Medicine · Darby, PA

NPI 1578844783

$109,952.85

in general payments reported to CMS, 2019-2025

32 companies · $106K in 2025

The $106K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$88,690.00
Travel and Lodging$12,436.98
Food and Beverage$8,081.19
Education$197.36
Gift$17.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $62,195.53 2022-2025 Nucala, Trelegy Ellipta
Astrazeneca Pharmaceuticals Lp $44,445.63 2019-2025 Breztri, Tezspire, Airsupra
Inari Medical, INC. $402.55 2023-2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Actelion Pharmaceuticals US, INC. $394.65 2024 Uptravi, Opsumit
Boehringer Ingelheim Pharmaceuticals, INC. $343.69 2023-2025 Ofev
Stryker Corporation $287.07 2025 Flowtriever Catheter, S, Ct Thrombectomy System Kit, Flowstasis
Grifols USA, LLC $207.94 2022-2025 Prolastin-C Liquid
Amgen INC. $207.03 2023-2025 Krystexxa, Tezspire, Evenity
Genentech USA, INC. $134.35 2019-2022
Ucb, INC. $134.27 2025 Bimzelx
Abbvie INC. $127.07 2023-2025 Ubrelvy
Baxter Healthcare $127.02 2023-2024 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Verona Pharma, INC. $120.19 2025 Ohtuvayre
Collegium Pharmaceutical, INC. $115.16 2024-2025 Belbuca
Regeneron Healthcare Solutions, INC. $96.12 2023 Dupixent
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Insmed, INC. $69.57 2025 Arikayce
Janssen Biotech, INC. $64.17 2024 Tremfya
Mylan Specialty L.P. $56.18 2023-2024 Yupelri
Genzyme Corporation $55.89 2023-2025
Electromed, INC. $47.64 2023-2024 Smartvest
Pfizer INC. $38.35 2023-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $35.36 2022
Vertex Pharmaceuticals Incorporated $33.10 2025
Pulmonx Corporation $32.76 2024 Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console
Boston Scientific Corporation $32.11 2024 Watchman Flx
Merck Sharp & Dohme LLC $28.94 2023 Keytruda
Viatris Specialty LLC $24.85 2025 Yupelri
Fresenius Kabi USA, LLC $24.39 2023
Valinor Pharma, LLC $19.99 2023 Movantik
Masimo Corporation $19.07 2023 Patient Safetynet System
Depuy Synthes Sales INC. $16.27 2024 Orthovisc
Novo Nordisk INC $15.94 2023 Ozempic, Rybelsus

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abhishek Bhardwaj

$109,952.85

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $106K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/750066/abhishek-bhardwaj

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.